Findings

What do systematic reviews say?

89 questions · 89 findings · 18 reviews · Gynaecological, Neuro-oncology and Orphan Cancer · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 12.4%GRADE not reported 3 · 3.4%Very low 21 · 23.6%Low 26 · 29.2%Moderate 17 · 19.1%High 11 · 12.4%

Cannabinoids vs placebo

Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids showed no clear difference in absence of nausea ( compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2 [0.2, 21]
2 studies · 96 participants
Low

Cannabinoids vs other anti‐emetic agent

Participant preference · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher participant preference ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2.8 [1.9, 4]
9 studies · 799 participants
Low

Cannabinoids vs other anti‐emetic agent

Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher withdrawal any reason ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 3.5 [1.4, 9]
1 study · 42 participants
Low

Cannabinoids vs other anti‐emetic agent

Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoids changes withdrawal due to lack of efficacy ( compared with other anti‐emetic agent (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 0.97 [0.04, 21]
2 studies · 118 participants
Very low

Cannabinoids vs other anti‐emetic agent

Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher withdrawal due to adverse event ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 3.2 [1.3, 8]
6 studies · 740 participants
Low

Cannabinoids vs placebo

Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher absence of vomiting ( compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 5.7 [2.6, 12.6]
3 studies · 168 participants
Low

Cannabinoids vs placebo

Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids probably leads to higher absence of nausea and vomiting ( compared with placebo (moderate certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2.9 [1.8, 4.7]
3 studies · 288 participants
Moderate

Cannabinoids vs placebo

Participant preference · people with chemotherapy‐induced nausea and vomiting

Cannabinoids may leads to higher participant preference ( compared with placebo (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 4.8 [1.7, 13]
2 studies · 256 participants
Low

Cannabinoids vs placebo

Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoids changes withdrawal any reason ( compared with placebo (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 0.31 [0.01, 7]
1 study · 33 participants
Very low

Cannabinoids vs placebo

Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoids changes withdrawal due to adverse event ( compared with placebo (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 6.9 [1.96, 24]
2 studies · 276 participants
Very low

Cannabinoids vs other anti‐emetic agent

Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids showed no clear difference in absence of nausea ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 1.46 [0.67, 3.15]
5 studies · 258 participants
Low

Cannabinoids vs other anti‐emetic agent

Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids showed no clear difference in absence of vomiting ( compared with other anti‐emetic agent (moderate certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 1.1 [0.86, 1.4]
4 studies · 209 participants
Moderate

Cannabinoids vs other anti‐emetic agent

Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoids showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic agent (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 2 [0.74, 5.4]
4 studies · 414 participants
Low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoid plus other anti‐emetic agent changes absence of nausea ( compared with other anti‐emetic monotherapy (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 10 [0.61, 183]
1 study · 37 participants
Very low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of vomiting ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 1.5 [0.69, 3.1]
2 studies · 89 participants
Low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 1.6 [0.68, 3.6]
1 study · 37 participants
Low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal any reason ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 1.3 [0.41, 4.2]
1 study · 41 participants
Low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting

It is very uncertain whether cannabinoid plus other anti‐emetic agent changes withdrawal due to adverse event ( compared with other anti‐emetic monotherapy (very low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 7 [0.88, 55]
2 studies · 105 participants
Very low

Cannabinoid plus other anti‐emetic agent vs other anti‐emetic monotherapy

Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting

Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal due to lack of efficacy ( compared with other anti‐emetic monotherapy (low certainty).

1 finding from 1 review

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy 2015 · Cochrane Headline outcomes only
RR 0.12 [0.01, 2]
1 study · 41 participants
Low

Summary of findings: Aminosalicylates vs placebo

Mean GI symptom scores (IBDQ‐B) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found